Mankind Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
January 31, 2024 at 07:08 am EST
Share
Mankind Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 26,069.59 million compared to INR 20,909.3 million a year ago. Revenue was INR 26,770.92 million compared to INR 21,280.74 million a year ago. Net income was INR 4,537.6 million compared to INR 2,841.52 million a year ago. Basic earnings per share from continuing operations was INR 11.33 compared to INR 7.09 a year ago. Diluted earnings per share from continuing operations was INR 11.31 compared to INR 7.09 a year ago.
For the nine months, sales was INR 78,936.75 million compared to INR 66,967.66 million a year ago. Revenue was INR 80,824.05 million compared to INR 67,778.22 million a year ago. Net income was INR 14,416.58 million compared to INR 9,964.21 million a year ago. Basic earnings per share from continuing operations was INR 35.99 compared to INR 24.87 a year ago. Diluted earnings per share from continuing operations was INR 35.94 compared to INR 24.87 a year ago.
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.